Abstract: The present invention is related to accurate detection methods for the measurement only of myeloperoxidase (MPO) levels or neutrophils, preferably equine neutrophils, in complex biological samples. The present invention is further related to ELISA and SIEFED assays for such detection. SIEFED detection sensitivity of active peroxidase activity was found to be enhanced by the addition of nitrite. Such MPO measurement finds its use in many applications such as the prediction, diagnosis and/or monitoring of pathologies correlated with neutrophil activation and/or destruction; the evaluation of drugs and/or immunomodulators; the assessment of immune responses, either natural and/or after treatment with immunomodulators and/or drugs; and the study of cells and their ability to fight microorganisms and/or to destroy them.
Abstract: The present invention relates to quality control methods using inorganic binding peptides, wherein inorganic entities are identified using inorganic-binding peptides specifically binding to the inorganic entity of interest. In particular, the invention includes a method for the identification of defects or inhomogeneities on a surface by detecting an inorganic entity of interest. It further includes a method for the isolation of powder particles comprising an inorganic entity of interest from a mixture of powder particles. In addition, the present invention relates to inorganic-binding peptides comprising the amino acid sequence MTWDPSLASPRS (SEQ ID NO: 31) and the amino acid sequence LNAAVPFTMAGS (SEQ ID NO: 32), respectively.
Type:
Application
Filed:
July 6, 2009
Publication date:
February 7, 2013
Applicants:
ARCELORMITTAL LIEGE RESEARCH, UNIVERSITE DE LIEGE INTERFACE ENTREPRISES UNIVERSITE
Inventors:
Christelle Vreuls, Cécile Van De Weerdt, Catherine Archembeau, André Renard, Joseph Martial
Abstract: The present disclosure relates to a pharmaceutical composition for use in the preventive and/or therapeutic treatment of thrombosis-related diseases or conditions relating to high level of plasminogen activator inhibitor 1 (PAI-1) expression, which composition comprises: A) a fragment of a polypeptide or protein of prolactin (PRL)-growth hormone (GH)-placental lactogen (PL)-family and homologous derivatives thereof, which fragment comprises from 6 to 14 consecutive amino acid residues of the amino acid sequence having general formula (I); or B) a peptide or a recombinant protein comprising said peptide, wherein the peptide is from 6 to 50 amino acids in length and has the activity to inhibit PAI-1, said peptide comprising from 6 to 14 consecutive amino acid residues of the amino acid sequence of general formula (I); or C) a polynucleotide encoding said fragment of a polypeptide or protein of A) or said peptide or recombinant protein of B).
Type:
Application
Filed:
February 16, 2011
Publication date:
February 7, 2013
Applicant:
UNIVERSITE DE LIEGE
Inventors:
Ingrid Struman, Joseph Martial, Khalid Bajou, Salvino D'Amico
Abstract: A method extracts out of an aqueous solution, concentrate and/or reformulate [18F] fluorides without any evaporation step. The eluting solution is a low water content, preferably <3% water, organic solution containing at least: a first compound (A) which is a tertiary alcohol-function bearing molecule, a second compound (B) which is a phase transfer agent suitable for radiolabeling and which is necessary to the anion exchange process.
Type:
Grant
Filed:
February 19, 2008
Date of Patent:
February 5, 2013
Assignees:
Trasis S.A., Universite de liege
Inventors:
Joel Aerts, Christian LeMaire, Steve Lignon, André Luxen, Jean-Luc Morelle, Gauthier Philippart, Samuel Voccia
Abstract: A method of producing a hydrogel for intra-articular supplement comprising the steps of: providing a solution of alginate, providing a solution with chitosan having a Mw between lower than 60 kD, mixing the solution of alginate and the solution of chitosan, wherein the mixed solution comprises between 0.5 and 0.7% (w/v) of chitosan and between 1 and 1.4% alginate (w/v), introducing droplets of the mixed solution into a solution with Ca2+ or Sr2+ cations and isolating polymerised beads from the solution with cations.
Type:
Application
Filed:
February 11, 2011
Publication date:
December 20, 2012
Applicants:
Kitozyme S.A., Universite de Liege
Inventors:
Yves Henrotin, Christelle Sanchez, Frederic Oprenyeszk, Pierre Drion
Abstract: Methods are described for improving the diagnostic possibilities of diseases where oxidative NO-modifications occur, for example inflammatory conditions, cancer, Parkinson's or Alzheimer's disease, and to provide means of monitoring the effects of therapeutical measures taken towards such diseases. The invention enables the detection of disease specific catabolic markers related to oxidative NO-modifications, utilizing an immunoassay comprising antibodies directed against nitrated and non-nitrated epitopes characteristic of a specific protein.
Type:
Grant
Filed:
August 30, 2011
Date of Patent:
December 11, 2012
Assignee:
Université de Liège
Inventors:
Jean-Yves Reginster, Michelle Deberg, Yves Henrotin, Stephan Christgau
Abstract: The invention provides the use of a cyclodextrin compound for the manufacturing of a medicament for the treatment or prevention of bronchial inflammatory diseases, particularly for asthma.
Abstract: The present invention describes a method to improve the properties of a dough and/or a baked product by adding a bread or dough-improving agent containing a enzyme with xylanolytic activity belonging to glycoside hydrolases family 8. Preferred enzymes are the psychrophilic xylanase from Pseudoalteromonas haloplanktis and the mesophilic xylanase Y from Bacillus halodurans C-125.
Type:
Grant
Filed:
August 25, 2010
Date of Patent:
November 13, 2012
Assignee:
Université de Liège
Inventors:
Tony Collins, Georges Feller, Charles Gerday, Marie-Alice Meuwis
Abstract: Method for the manufacture of carbon nanotubes by thermal decomposition of at least one gaseous hydrocarbon (14) in the presence of a solid catalyst in a reactor (4) into which the catalyst is introduced via an inlet lock chamber (17) flushed by an inert gas (21, 22, 25, 26) and from which the carbon nanotubes are withdrawn via an outlet lock chamber (37) which is flushed with a flow of inert gas (39, 40).
Type:
Application
Filed:
June 5, 2012
Publication date:
October 25, 2012
Applicant:
Universite de Liege, Interface Entreprises-Universite
Inventors:
Jean-Paul Pirard, Christophe Bossuot, Patrick Kreit
Abstract: A first object of the invention is a radiation detector comprising an energy absorber (203), for absorbing incident radiation (RAD) and thus undergoing a temperature increase; and optical readout means, for detecting said temperature increase; wherein said optical readout means comprises input coupling means (202) for coupling a light beam (2011) to said energy absorber (203) by exciting surface plasmons resonance, a surface plasmons resonance condition being dependent on the energy absorber (203) temperature, and wherein said energy absorber (203) is separated from said input coupling means (202) by a dielectric layer (2032).
Type:
Grant
Filed:
May 24, 2007
Date of Patent:
August 14, 2012
Assignee:
Université de Liège
Inventors:
Karl Fleury-Frenette, Serge Habraken, Yvon Renotte, Jurij Hastanin
Abstract: Method for the manufacture of carbon nanotubes by thermal decomposition of at least one gaseous hydrocarbon (14) in the presence of a solid catalyst in a reactor (4) into which the catalyst is introduced via an inlet lock chamber (17) flushed by an inert gas (21, 22, 25, 26) and from which the carbon nanotubes are withdrawn via an outlet lock chamber (37) which is flushed with a flow of inert gas (39, 40).
Type:
Grant
Filed:
August 4, 2005
Date of Patent:
August 14, 2012
Assignee:
Universite de Liege, Interface Enterprises-Universite
Inventors:
Jean-Paul Pirard, Christophe Bossuot, Patrick Kreit
Abstract: A lightweight and energetically autonomous device for real-time monitoring of overhead power lines, comprising:—an external housing (EMS1) provided, at opposed ends thereof, with a first (OP1) and a second (OP2) opening for a power line cable (HVC) traversing said external housing; a monitoring subsystem (B) for monitoring at least a mechanical parameter of said overhead power line; and—a communication subsystem (D) for transmitting monitoring information generated by said monitoring subsystem; characterized in that: an internal housing (EMS2) is provided within said external housing (EMS1), said power line cable (HVC) passing outside said internal housing (EMS2); said monitoring subsystem (B) is disposed within said internal housing (EMS2); said external (EMS1) and internal (EMS2) housings are both made of a conducting material in order to form electromagnetic shields; and said monitoring subsystem (B) comprises at least an oscillation sensor for detecting mechanical oscillations of said power line cable (HV
Abstract: The invention concerns an isolated complex comprising an HIV or HTLV protein and a human protein. Corresponding nucleic acids, vectors, host cells, host organisms, compositions, kits, medical uses, diagnostic uses, and methods of screening agents are also contemplated. Disclosed are 212 interactions between 19 retroviral proteins and 131 human proteins.
Abstract: The present invention relates to a process for the production of a functional food additive, such as a prebiotic composition, comprising the steps of.
Type:
Application
Filed:
January 19, 2010
Publication date:
February 9, 2012
Applicant:
Universite de Liege Gembloux Agro-Bio Tech
Inventors:
Dorothée Goffin, Michel Paquot, Christophe Blecker, Christelle Robert
Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
Type:
Application
Filed:
January 15, 2010
Publication date:
January 19, 2012
Applicants:
UNIVERSITE DE LIEGE, UNIVERSITE LIBRE DE BRUXELLES, CENTRE D'ECONOMIE RURALE
Inventors:
Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
Abstract: The present invention refers to a recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3), which is immunogenic in fish, preferably in carps, more preferably in Cyprinus carpio, and to a vaccine for preventive and/or therapeutic treatment of a disease caused by koi herpesvirus (KHV) or CyHV-3. The 5 recombinant herpesvirus is used to confer immunity on fish, preferably on carps, more preferably on Cyprinus carpio, against a disease caused by koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3).
Type:
Application
Filed:
August 26, 2008
Publication date:
November 24, 2011
Applicant:
Universite de Liege, Faculty of Veterinary Medicine immunology-Vaccinology
Inventors:
Berenice Costes, Alain Francis Claude Vanderplasschen, Francois Lieffrig
Abstract: A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility.
Type:
Grant
Filed:
May 27, 2009
Date of Patent:
October 25, 2011
Assignee:
Universite De Liege
Inventors:
Pierre Bartsch, Didier Cataldo, Richard Endele, Brigitte Evrard, Jean-Michel Foidart, Hans-Willi Krell, Gerd Zimmermann
Abstract: The present invention relates to the medical field. In a first aspect the present invention relates to novel water soluble cyclodextrin-curcumin complexes having a pharmacological activity, in particular an anti-tumour and/or anti-inflammatory activity, and improved physico-chemical properties. In a second aspect, the present invention relates to a method for preparation of said water soluble curcumin derivatives. The invention further relates in a third aspect to a pharmaceutical composition comprising an effective amount of said water soluble curcumin derivatives. In a fourth aspect, the present invention concerns the use of said water soluble cucumin derivatives as a medicament and the use of said water soluble curcumin derivatives for the preparation of a medicament for the treatment of cancer and inflammatory diseases.
Type:
Application
Filed:
May 26, 2009
Publication date:
October 20, 2011
Applicants:
Universite de Liege, Universite Libre de Bruxelles
Inventors:
Philippe Neven, Didier Serteyn, Jacques Delarge, Eva Scheer, Robert Kiss, Veronique Mathieu, Didier Cataldo, Natacha Rocks
Abstract: The present invention relates to a Visual Background Extractor (VIBE) consisting in a method for detecting a background in an image selected from a plurality of related images. Each one of said set of images is formed by a set of pixels, and captured by an imaging device.
Type:
Grant
Filed:
June 16, 2008
Date of Patent:
August 30, 2011
Assignee:
Universite De Liege
Inventors:
Marc Van Droogenbroeck, Olivier Barnich
Abstract: A probiotic composition comprising a Bifidobacterium strain which has DNA sequence homology of greater than 40% to Bifidobacterium GC56, wherein Bifidobacterium GC56 was deposited at the Collection Nationale de Cultures de Micro-organismes (CNCM, Institut Pasteur) on 9 Dec. 2004 with accession number CNCM 1-3342.
Type:
Grant
Filed:
March 31, 2006
Date of Patent:
June 14, 2011
Assignee:
Universite de Liege
Inventors:
Georges Daube, Veronique Delcenserie, Françoise Gavini